Sollis Therapeutics

What Sollis Therapeutics does

Sollis Therapeutics is a privately held, clinical-stage pharmaceutical company founded in 2017 and headquartered in Columbus, Ohio, focused on developing non-opioid analgesic solutions. The company's stated therapeutic focus addresses a significant unmet need in pain management by targeting alternatives to opioid-based therapies, a category with substantial regulatory and commercial tailwinds given the ongoing opioid crisis and tightening prescribing norms.

The company operates with a lean organizational footprint of 1–10 employees and a small senior leadership team consisting of President & CEO Alex Dinello, COO Bryan Jones, and co-founder/director Kevin Wasserstein. Its capital base was established primarily through a $50,000,000 funding round in April 2018 led by Deerfield with participation from Neurotechnology Innovations Translator, followed by a smaller $2,500,000 raise in March 2021. The investor profile — anchored by Deerfield, a specialist healthcare investor — signals institutional validation of the underlying science and development plan, while the presence of Neurotechnology Innovations Translator suggests a neurotechnology component to the therapeutic approach.

Sollis's revenue model is not publicly disclosed and the available source data does not list any commercialized products, named customers, partnerships, or pricing structures. The cumulative disclosed funding of approximately $52.5M is consistent with capital deployed into preclinical or early-clinical R&D rather than commercial operations. As a result, the company should be treated as a development-stage entity whose near-term economics depend on advancing clinical milestones, securing additional financing, or executing a strategic transaction, rather than on current product revenue.

Name

Sollis Therapeutics

Website

https://sollistx.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Short description

Sollis Therapeutics is a privately held, clinical-stage pharmaceutical company founded in 2017 in Columbus, Ohio, developing non-opioid analgesic solutions for the pain management market. The company operates with 1–10 employees and has raised approximately $52.5M to date, led by Deerfield.

Ownership category

akta.pro rank

Product category

Non-Opioid Pain Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Non-opioid analgesics
• Pain management therapeutics
• Pharmaceutical drug development
• Clinical-stage biopharmaceutical
• Nerve pain treatments

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Sollis Therapeutics is a clinical-stage pharmaceutical company developing non-opioid analgesic drug candidates for the treatment of pain conditions. The company's core focus is on creating therapeutics that address pain without the addiction risks and side effects associated with traditional opioid-based medications. The company is currently in the drug development phase, backed by specialized healthcare investors.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-opioid analgesic drug candidates Clinical-stage pharmaceutical drug candidates targeting pain conditions through non-opioid mechanisms, designed to provide pain management without the addiction risks and side effects associated with opioid-based medications. Targeted at pharmaceutical partners for licensing/co-development and ultimately at healthcare providers and patients for pain management.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sollis Therapeutics